GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

GAZYVA + bendamustine followed by GAZYVA monotherapy demonstrated a longer median duration of response vs bendamustine alone 1

GAZYVA GADOLIN Secondary Endpoint: Duration of Response Chart